Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

VIC-1911

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Otsuka, VITRAC Therap

Drug class:

Aurora kinase A inhibitor

Related drugs:

CTNNB1 mutation	Lung Cancer	CTNNB1 mutation	Lung Cancer	VIC-1911 Sensitive: D – Preclinical VIC-1911 Sensitive : D	VIC-1911 Sensitive: D – Preclinical VIC-1911 Sensitive : D
CDKN2A mutation	Squamous Cell Carcinoma of Head and Neck	CDKN2A mutation	Squamous Cell Carcinoma of Head and Neck	AZD1775 + VIC-1911 Sensitive: D – Preclinical AZD1775 + VIC-1911 Sensitive : D	AZD1775 + VIC-1911 Sensitive: D – Preclinical AZD1775 + VIC-1911 Sensitive : D
TP53 mutation	Small Cell Lung Cancer	TP53 mutation	Small Cell Lung Cancer	AZD1775 + VIC-1911 Sensitive: D – Preclinical AZD1775 + VIC-1911 Sensitive : D	AZD1775 + VIC-1911 Sensitive: D – Preclinical AZD1775 + VIC-1911 Sensitive : D
TP53 mutation	Squamous Cell Carcinoma of Head and Neck	TP53 mutation	Squamous Cell Carcinoma of Head and Neck	AZD1775 + VIC-1911 Sensitive: D – Preclinical AZD1775 + VIC-1911 Sensitive : D	AZD1775 + VIC-1911 Sensitive: D – Preclinical AZD1775 + VIC-1911 Sensitive : D
CDKN2A mutation	Non Small Cell Lung Cancer	CDKN2A mutation	Non Small Cell Lung Cancer	AZD1775 + VIC-1911 Sensitive: D – Preclinical AZD1775 + VIC-1911 Sensitive : D	AZD1775 + VIC-1911 Sensitive: D – Preclinical AZD1775 + VIC-1911 Sensitive : D
KRAS G12C	Non Small Cell Lung Cancer	KRAS G12C	Non Small Cell Lung Cancer	sotorasib + VIC-1911 Sensitive: D – Preclinical sotorasib + VIC-1911 Sensitive : D	sotorasib + VIC-1911 Sensitive: D – Preclinical sotorasib + VIC-1911 Sensitive : D